NCT06783088Completed
Quantification With Lutetium-177 on Cadmium-Zinc-Telluride Camera 3D
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
The main of this study is to demonstrate the feasibility of carrying out quantitative acquisitions regardless of the energy peak considered (113 keV (kiloelectronVolts) or 208 keV or a combination of the 2 energy peaks). A study on phantom will optimise the reconstruction parameters. These parameters will then be applied to a population of patients who have already benefited from a recording on a 3D CZT camera (retrospective data).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 20 (actual)
- First submitted
- 14 Jan 2025
- Start date
- 10 Mar 2025
- Primary completion date
- 10 Apr 2025
- Lead sponsor
- Central Hospital, Nancy, France
- Diseases
- Prostate cancer
- NCT number
- NCT06783088
What you commit to
- Study type: Observational
- Participants enrolled: 20
- From 10 Mar 2025 to the primary completion date, 10 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient having sent an objection to the use of their data
Who the study is looking for
- Patients treated by at least one cure of lutetium vipivotide tetraxetan with imaging
Criteria the registry did not label
- It is a retrospective study and the criteria to collect the imaging are:
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHRU Nancy Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.